# A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol

> **NCT05127304** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 11316 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DEVICE:** Trelegy Ellipta
- **DEVICE:** Stiolto Respimat
- **DRUG:** Furoate/Umeclidinium/Vilanterol
- **DRUG:** Tiotropium Bromide/Olodaterol

## Key facts

- **NCT ID:** NCT05127304
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-26
- **Primary completion:** 2022-02-03
- **Final completion:** 2022-02-03
- **Target enrollment:** 11316 (ACTUAL)
- **Last updated:** 2023-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05127304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05127304, "A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05127304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*